Company / Net Income
Lilly (Eli) Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$20.6B
FY2025
5-year range
$5.6B / $20.6B
FY2021-FY2025
Trend
+94.9%
vs FY2024
Sector context
#2 of 216
Health Care
What the data says
Among 216 Health Care companies, Lilly (Eli) is in the top 1% for net income. Net Income has fluctuated over the past 10 years, ranging from $2.4B in FY2017 to $20.6B in FY2025.
Based on SEC 10-K filings.
$20.6B in FY2025 with a 5-year CAGR of +44.9%. Ranks 2nd among 216 companies in Health Care.
Improved from $5.6B to $20.6B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +49.4%
- 5-Year CAGR
- +44.9%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 216This company $20.6B Sector average $454.1M
▼
+4445.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +44.9%, indicating consistent growth.
- In FY2025, net income increased 94.9% year-over-year.
- Ranks #2 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 1.02 (distress zone, below 1.8 threshold)
- Strong profit margin: 31.0%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 77.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.6B | +94.9% |
| FY2024 | $10.6B | +89.7% |
| FY2023 | $5.6B | -9.9% |
| FY2022 | $6.2B | -25.5% |
| FY2021 | $8.3B | +157.4% |
| FY2020 | $3.2B | -61.1% |
| FY2019 | $8.3B | +157.4% |
| FY2018 | $3.2B | +34.2% |
| FY2017 | $2.4B | -12.0% |
| FY2016 | $2.7B | +13.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026